Navigation Links
Cytopia Merger with Toronto-based YM BioSciences Inc.
Date:10/5/2009

al being announced.
  • Each of Cytopia and YM has agreed to the payment of a break fee of A$500,000 under certain circumstances.
  • For the period commencing on the date of the Agreement until the earlier of termination of the Agreement or 28 February 2010, Cytopia has agreed not to solicit, encourage, initiate or participate in any negotiations or discussions in respect of an expression of interest, offer or proposal for an alternative transaction to the Scheme(s) (subject to the fiduciary duties of Cytopia's directors).
  • On successful implementation of the Scheme(s), Cytopia will be delisted from ASX.
  • Full details of the merger will be provided to Cytopia shareholders and optionholders in a Scheme Booklet which is expected to be distributed in late November 2009. The Scheme Booklet will include the report from the independent expert and will further explain the basis for the proposed merger.

    It is expected that shareholders, and optionholders if necessary, will be asked to vote on the approval of the Scheme(s) in January 2010.

    Cytopia has appointed Clayton Utz as Australian legal adviser, Toronto-based Blake, Cassels & Graydon LLP as Canadian legal adviser, US-based Oppenheimer & Co Inc as financial advisor and Lonergan Edwards as an independent expert.

    About Cytopia

    Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Australia and the USA and specialises in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

    The lead program for the company is CYT997, a vascular disrupting agent for the treatment of various cancers, and currently being trialled in Phase II clinical studies. Cytopia also is building on its range of JAK inhibitors
    '/>"/>

    SOURCE Cytopia Ltd.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
    2. Cytopia Presentation on VDA CYT997 at AACR Conference
    3. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
    4. Cytopia Letter to Progen Shareholders
    5. Cytopia and Other Progen Shareholders Maintain Call for Meeting
    6. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
    7. Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist
    8. Cytopia Presentation on JAK2 Inhibitor at American Association for Cancer Research
    9. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
    10. Schering-Plough Shareholders Approve Merger With Merck
    11. TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/1/2015)... 1, 2015 A new report ... drugs will reach $22.4bn in 2019. That revenue forecast ... and Market Prospects 2015-2025 ,  published in ... is to provide forecasts and qualitative analyses of the ... and consultancy in London, UK . ...
    (Date:4/30/2015)... Spirax Sarco, the leader in product ... announce that for the first time in the company’s ... a Queen’s Award for Innovation – the UK’s highest ... of a unique flowmeter. , The Spirax Sarco ... steam flow measurement. The device provides reliable, accurate ...
    (Date:4/30/2015)... 30, 2015 Nitto Avecia, a ... its increased capacity and production capability to serve ... variety and service fulfillment continues to drive Nitto ... process throughput capacities. , In Fall ... downstream process equipment at its Milford, MA facility, ...
    (Date:4/30/2015)... SAN DIEGO , April 30, 2015 /PRNewswire/ ... company engaged in the development of biosimilar therapeutics ... today announced the closing of its previously announced ... common stock at a public offering price of ... full by the underwriters of their option to ...
    Breaking Biology Technology:Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2
    ... March 17 VION,PHARMACEUTICALS, INC. (Nasdaq: VIOND ) ... of 2007., The Company reported a net loss ... ended December 31, 2007, compared with a net loss ... common shares,outstanding for the years ended December 31, 2007 ...
    ... panel for assessment of current risk ... ... Limited (TSX: GEN),a company focused on developing molecular diagnostic tests ... diseases and personalized,health management, today announced that its abstract describing ...
    ... Axial Biotech, Inc., a company,revolutionizing spine care ... technologies, announced today that it has met several,major ... genetic,prognostic test for Adolescent Idiopathic Scoliosis (AIS) and ... B financing. The Series B financing was,led by ...
    Cached Biology Technology:Vion Reports 2007 Fourth Quarter and Year-End Results 2Vion Reports 2007 Fourth Quarter and Year-End Results 3Vion Reports 2007 Fourth Quarter and Year-End Results 4GeneNews selected to present late-breaking abstract at AACR Annual Meeting 2Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing 2
    (Date:4/2/2015)... , April 2, 2015 At its 2015 ... Lake City , the American College of Medical ... new directors to its Board.  Members of the ACMG ... and for forming and advancing its policies and programs. ... profession. "It,s an eventful time in medical ...
    (Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
    (Date:3/31/2015)... --  Guidepoint , a leading global research services firm, ... TRACKER, part of the Guidepoint TRACKER suite ... device and therapeutics markets. The Post-Surgical Pain Management TRACKER ... share, and adoption rates across three major modalities used ... The Post-Surgical Pain Management TRACKER will provide length ...
    Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
    ... Although the two disorders may seem dissimilar, epilepsy and ... to have schizophrenia, and a family history of epilepsy ... known whether the converse is true, i.e., whether a ... epilepsy. Multiple studies using varied investigative techniques ...
    ... Cracking the Neural Code: Third Annual Aspen Brain Forum ... of Sciences and The Aspen Brain Forum Foundation WHEN: ... www.nyas.org/NeuralCode One of the greatest challenges in neuroscience ... neuronal circuits gives rise to higher order cognition and behavior. ...
    ... - New research suggests that there could be health ... This antioxidant is a naturally occurring pigment that gives ... certain greens. It also converts to vitamin A, and ... essential nutrient. But scientists at Ohio State University ...
    Cached Biology News:Evidence of familial vulnerability for epilepsy and psychosis 2Researchers find potential 'dark side' to diets high in beta-carotene 2Researchers find potential 'dark side' to diets high in beta-carotene 3Researchers find potential 'dark side' to diets high in beta-carotene 4
    Request Info...
    Immunogen: VDAC3 Protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
    ... 75 x 25 mm; ... recommended for immunohistochemistry of paraffin-embedded sections, ... end, markings will not ... precleaned, ...
    Complete cell culture media with cytokines...
    Biology Products: